Loading...

Orapi

ENXTPA:ORAP
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ORAP
ENXTPA
€22M
Market Cap
  1. Home
  2. FR
  3. Materials
Company description

Orapi, together with its subsidiaries, designs, manufactures, and sells products for professional hygiene, maintenance, and industrial processes worldwide. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Orapi has significant price volatility in the past 3 months.
ORAP Share Price and Events
7 Day Returns
-3.9%
ENXTPA:ORAP
3.7%
FR Chemicals
1.9%
FR Market
1 Year Returns
-49%
ENXTPA:ORAP
0.2%
FR Chemicals
-2.3%
FR Market
ORAP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Orapi (ORAP) -3.9% -7.5% 2.5% -49% -37.5% -72.8%
FR Chemicals 3.7% -1.8% 8.7% 0.2% 31.3% 32.1%
FR Market 1.9% -2.3% 5.9% -2.3% 30.8% 29.8%
1 Year Return vs Industry and Market
  • ORAP underperformed the Chemicals industry which returned 0.2% over the past year.
  • ORAP underperformed the Market in France which returned -2.3% over the past year.
Price Volatility
ORAP
Industry
5yr Volatility vs Market

Value

 Is Orapi undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Orapi to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Orapi.

ENXTPA:ORAP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 14%
Perpetual Growth Rate 10-Year FR Government Bond Rate 0.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ENXTPA:ORAP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year FR Govt Bond Rate 0.7%
Equity Risk Premium S&P Global 6.7%
Chemicals Unlevered Beta Simply Wall St/ S&P Global 0.87
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.873 (1 + (1- 33%) (359.85%))
2.325
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.73% + (2 * 6.65%)
14.03%

Discounted Cash Flow Calculation for ENXTPA:ORAP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Orapi is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ENXTPA:ORAP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 14.03%)
2019 7.90 Analyst x1 6.93
2020 4.80 Analyst x1 3.69
2021 6.70 Analyst x1 4.52
2022 8.27 Est @ 23.37% 4.89
2023 9.64 Est @ 16.58% 5.00
2024 10.77 Est @ 11.82% 4.90
2025 11.69 Est @ 8.5% 4.66
2026 12.41 Est @ 6.17% 4.34
2027 12.97 Est @ 4.54% 3.98
2028 13.41 Est @ 3.4% 3.61
Present value of next 10 years cash flows €46.51
ENXTPA:ORAP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €13.41 × (1 + 0.73%) ÷ (14.03% – 0.73%)
€101.60
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €101.60 ÷ (1 + 14.03%)10
€27.33
ENXTPA:ORAP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €46.51 + €27.33
€73.84
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €73.84 / 4.58
€16.11
ENXTPA:ORAP Discount to Share Price
Calculation Result
Value per share (EUR) From above. €16.11
Current discount Discount to share price of €4.90
= -1 x (€4.90 - €16.11) / €16.11
69.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Orapi is available for.
Intrinsic value
>50%
Share price is €4.9 vs Future cash flow value of €16.11
Current Discount Checks
For Orapi to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Orapi's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Orapi's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Orapi's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Orapi's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:ORAP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-0.82
ENXTPA:ORAP Share Price ** ENXTPA (2019-05-17) in EUR €4.9
France Chemicals Industry PE Ratio Median Figure of 9 Publicly-Listed Chemicals Companies 20.66x
France Market PE Ratio Median Figure of 418 Publicly-Listed Companies 17.81x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Orapi.

ENXTPA:ORAP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ORAP Share Price ÷ EPS (both in EUR)

= 4.9 ÷ -0.82

-5.98x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orapi is loss making, we can't compare its value to the FR Chemicals industry average.
  • Orapi is loss making, we can't compare the value of its earnings to the France market.
Price based on expected Growth
Does Orapi's expected growth come at a high price?
Raw Data
ENXTPA:ORAP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.98x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
76.7%per year
France Chemicals Industry PEG Ratio Median Figure of 7 Publicly-Listed Chemicals Companies 1.7x
France Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Orapi, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Orapi's assets?
Raw Data
ENXTPA:ORAP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €9.35
ENXTPA:ORAP Share Price * ENXTPA (2019-05-17) in EUR €4.9
France Chemicals Industry PB Ratio Median Figure of 17 Publicly-Listed Chemicals Companies 1.82x
France Market PB Ratio Median Figure of 619 Publicly-Listed Companies 1.44x
ENXTPA:ORAP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ORAP Share Price ÷ Book Value per Share (both in EUR)

= 4.9 ÷ 9.35

0.52x

* Primary Listing of Orapi.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Orapi is good value based on assets compared to the FR Chemicals industry average.
X
Value checks
We assess Orapi's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Chemicals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Chemicals industry average (and greater than 0)? (1 check)
  5. Orapi has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Orapi expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
76.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Orapi expected to grow at an attractive rate?
  • Orapi's earnings growth is expected to exceed the low risk savings rate of 0.7%.
Growth vs Market Checks
  • Orapi's earnings growth is expected to exceed the France market average.
  • Orapi's revenue growth is positive but not above the France market average.
Annual Growth Rates Comparison
Raw Data
ENXTPA:ORAP Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTPA:ORAP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 76.7%
ENXTPA:ORAP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 2.3%
France Chemicals Industry Earnings Growth Rate Market Cap Weighted Average 10.1%
France Chemicals Industry Revenue Growth Rate Market Cap Weighted Average 4.8%
France Market Earnings Growth Rate Market Cap Weighted Average 13.2%
France Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:ORAP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:ORAP Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 273 13 5 1
2020-12-31 265 9 1 1
2019-12-31 255 4 3 1
ENXTPA:ORAP Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 256 2 -4
2018-09-30 251 -4
2018-06-30 247 2 -4
2018-03-31 245 4 -3
2017-12-31 244 6 -2
2017-09-30 243 -1
2017-06-30 242 9 0
2017-03-31 245 6 -1
2016-12-31 248 3 -1
2016-09-30 255 1 -3
2016-06-30 263 -1 -4
2016-03-31 270 1 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Orapi's earnings are expected to grow significantly at over 20% yearly.
  • Orapi's revenue is expected to grow by 2.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:ORAP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Orapi Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:ORAP Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 1.14 1.14 1.14 1.00
2020-12-31 0.32 0.32 0.32 1.00
2019-12-31 0.62 0.62 0.62 1.00
ENXTPA:ORAP Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -0.82
2018-09-30 -0.80
2018-06-30 -0.79
2018-03-31 -0.62
2017-12-31 -0.46
2017-09-30 -0.27
2017-06-30 -0.09
2017-03-31 -0.17
2016-12-31 -0.24
2016-09-30 -0.57
2016-06-30 -0.90
2016-03-31 -1.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Orapi is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Orapi's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Orapi has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Orapi performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Orapi's growth in the last year to its industry (Chemicals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Orapi does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Orapi's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Orapi's 1-year growth to the FR Chemicals industry average as it is not currently profitable.
Earnings and Revenue History
Orapi's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Orapi Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:ORAP Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 255.93 -3.76 110.32
2018-09-30 251.36 -3.68 109.68
2018-06-30 246.79 -3.61 109.04
2018-03-31 245.26 -2.86 108.84
2017-12-31 243.73 -2.11 108.64
2017-09-30 242.92 -1.26 109.00
2017-06-30 242.11 -0.42 109.36
2017-03-31 245.10 -0.76 111.09
2016-12-31 248.09 -1.10 112.81
2016-09-30 255.47 -2.61 115.81
2016-06-30 262.85 -4.12 118.81
2016-03-31 270.01 -4.85 122.48
2015-12-31 277.17 -5.58 126.14
2015-09-30 264.64 -3.35 121.30
2015-06-30 252.11 -1.13 116.47
2015-03-31 236.16 0.41 110.49
2014-12-31 220.22 1.94 104.51
2014-09-30 220.38 2.00 104.58
2014-06-30 220.54 2.05 104.65
2014-03-31 215.60 2.66 102.76
2013-12-31 210.66 3.26 100.88
2013-09-30 207.02 3.12 100.28
2013-06-30 203.38 2.97 99.69
2013-03-31 187.55 2.53 92.65
2012-12-31 171.73 2.08 85.61
2012-09-30 152.42 1.78 76.92
2012-06-30 133.12 1.48 68.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Orapi has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Orapi has efficiently used its assets last year compared to the FR Chemicals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Orapi improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Orapi's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Chemicals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Orapi has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Orapi's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Orapi's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Orapi is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Orapi's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Orapi's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Orapi Company Filings, last reported 4 months ago.

ENXTPA:ORAP Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 43.00 80.83 8.55
2018-09-30 43.00 80.83 8.55
2018-06-30 45.33 80.56 4.73
2018-03-31 45.33 80.56 4.73
2017-12-31 46.41 72.84 9.76
2017-09-30 46.41 72.84 9.76
2017-06-30 48.85 70.20 5.31
2017-03-31 48.85 70.20 5.31
2016-12-31 48.80 62.29 6.66
2016-09-30 48.80 62.29 6.66
2016-06-30 49.39 75.04 13.13
2016-03-31 49.39 75.04 13.13
2015-12-31 50.81 62.87 12.64
2015-09-30 50.81 62.87 12.64
2015-06-30 54.96 65.73 12.67
2015-03-31 54.96 65.73 12.67
2014-12-31 49.32 44.53 6.96
2014-09-30 49.32 44.53 6.96
2014-06-30 40.68 53.06 6.62
2014-03-31 40.68 53.06 6.62
2013-12-31 41.08 49.46 5.68
2013-09-30 41.08 49.46 5.68
2013-06-30 40.16 47.14 4.45
2013-03-31 40.16 47.14 4.45
2012-12-31 38.95 41.67 5.78
2012-09-30 38.95 41.67 5.78
2012-06-30 36.37 46.46 4.85
  • Orapi's level of debt (188%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (120.5% vs 188% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Orapi has sufficient cash runway for 1.5 years based on current free cash flow.
  • Orapi has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 9.8% each year.
X
Financial health checks
We assess Orapi's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Orapi has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Orapi's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Orapi dividends. Estimated to be 0% next year.
If you bought €2,000 of Orapi shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Orapi's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Orapi's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:ORAP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
France Chemicals Industry Average Dividend Yield Market Cap Weighted Average of 7 Stocks 2.3%
France Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3.1%
France Minimum Threshold Dividend Yield 10th Percentile 1%
France Bottom 25% Dividend Yield 25th Percentile 1.6%
France Top 25% Dividend Yield 75th Percentile 4.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTPA:ORAP Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
ENXTPA:ORAP Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2016-09-14 0.000 0.000
2016-04-05 0.000 0.000
2015-04-02 0.130 1.403
2015-03-18 0.130 1.167
2014-04-02 0.500 3.582
2014-03-18 0.500 2.820
2013-04-02 0.460 3.526
2013-03-19 0.460 4.338
2012-04-04 0.350 3.247
2012-03-29 0.350 2.482
2011-03-30 0.350 2.460
2011-01-17 0.350 2.263
2010-04-06 0.250 1.743
2010-01-15 0.250 1.750
2009-10-08 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Orapi has not reported any payouts.
  • Unable to verify if Orapi's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Orapi's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Orapi has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Orapi's dividends in 3 years as they are not expected to pay a notable one for France.
X
Income/ dividend checks
We assess Orapi's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Orapi afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Orapi has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Orapi's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Guy Chifflot
COMPENSATION €348,000
CEO Bio

Mr. Monsieur Guy Chifflot serves as the Chairman, Chief Executive Officer and President of Orapi. Mr. Chifflot serves as a Manager of ORAPI Europe and Orapi International. Mr. Chifflot serves as the Managing Director and Chairman of Laboratoires Meyssol SA. he served as Managing Director of Orapi. He also serves as a Director of Orapi.

CEO Compensation
  • Insufficient data for Guy to compare compensation growth.
  • Guy's remuneration is lower than average for companies of similar size in France.
Management Team

Fabienne Chifflot

TITLE
Head of Communications & Director
COMPENSATION
€48K

Henri Biscarrat

TITLE
Deputy CEO & Director
COMPENSATION
€258K

Fabrice Chifflot

TITLE
Director and Managing Director of Asia & Middle East
COMPENSATION
€252K

Martin Duncan

TITLE
Director of North Europe Region
COMPENSATION
€201K

Guy Chifflot

TITLE
Chairman of the Board
COMPENSATION
€348K

Philippe Montagnier

TITLE
Director of Human Resources
Board of Directors Tenure

Average tenure of the Orapi board of directors in years:

6.1
Average Tenure
  • The tenure for the Orapi board of directors is about average.
Board of Directors

Fabienne Chifflot

TITLE
Head of Communications & Director
COMPENSATION
€48K

Henri Biscarrat

TITLE
Deputy CEO & Director
COMPENSATION
€258K
TENURE
9.1 yrs

Fabrice Chifflot

TITLE
Director and Managing Director of Asia & Middle East
COMPENSATION
€252K

Guy Chifflot

TITLE
Chairman of the Board
COMPENSATION
€348K

René Perrin

TITLE
Director
COMPENSATION
€2K
TENURE
17 yrs

Jean-Pierre Gaillard

TITLE
Director
COMPENSATION
€2K
TENURE
6.1 yrs

Carole Dufour

TITLE
Director
COMPENSATION
€2K
TENURE
4.1 yrs

Antonin Beurrier

TITLE
Director
COMPENSATION
€2K
AGE
48
TENURE
4.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Orapi's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Orapi has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Kind Of Shareholders Own Orapi (EPA:ORAP)?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Companies that have been privatized tend to have low insider ownership. … With a market capitalization of €27m, Orapi is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Such Is Life: How Orapi Shareholders Saw Their Shares Drop 68%

It's nice to see the Orapi (EPA:ORAP) share price up 11% in a week. … Indeed, the share price is down 68% in the period. … A more detailed examination of the revenue and earnings may or may not explain why the share price languishes; there could be an opportunity.

Simply Wall St -

One Thing To Remember About The Orapi (EPA:ORAP) Share Price

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider. … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Is Orapi (EPA:ORAP) Investing Your Capital Efficiently?

In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. … What is Return On Capital Employed (ROCE)? … ROCE measures the amount of pre-tax profits a company can generate from the capital employed in its business.

Simply Wall St -

Could Orapi's (EPA:ORAP) Investor Composition Influence The Stock Price?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … We also tend to see lower insider ownership in companies that were previously publicly owned. … institutional investors have bought into the company.

Simply Wall St -

Loss-Making Orapi (EPA:ORAP) Expected To Breakeven

The company’s loss has recently broadened since it announced a -€2m loss in the full financial year, compared to the latest trailing-twelve-month loss of -€4m, moving it further away from breakeven? … The most pressing concern for investors is ORAP’s path to profitability – when will it breakeven. … I’ve put together a brief outline of industry analyst expectations for ORAP, its year of breakeven and its implied growth rate

Simply Wall St -

Who Are The Largest Shareholders In Orapi (EPA:ORAP)?

In this analysis, my focus will be on developing a perspective on Orapi’s (EPA:ORAP) latest ownership structure, a less discussed, but important factor. … Ownership structure of a company has been found to affect share performance over time. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

Is It Too Late To Buy Orapi (EPA:ORAP)?

saw significant share price volatility over the past couple of months on the ENXTPA, rising to the highs of €10.4 and falling to the lows of €8.76. … A question to answer is whether Orapi's current trading price of €8.88 reflective of the actual value of the? … Let’s take a look at Orapi’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change

Simply Wall St -

When Can We Expect A Profit From Orapi (ENXTPA:ORAP)?

The most pressing concern for investors is ORAP’s path to profitability – when will it breakeven. … I’ve put together a brief outline of industry analyst expectations for ORAP, its year of breakeven and its implied growth rate … According to the industry analysts covering ORAP, breakeven is near.

Simply Wall St -

Is It The Right Time To Buy Orapi (EPA:ORAP)?

According to my valuation model, Orapi seems to be fairly priced at around 20% above my intrinsic value, which means if you buy Orapi today, you’d be paying a relatively reasonable price for it. … It seems like the market has already priced in ORAP’s positive outlook, with shares trading around its fair value. … However, the positive outlook is encouraging for the company, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

Simply Wall St -

Company Info

Description

Orapi, together with its subsidiaries, designs, manufactures, and sells products for professional hygiene, maintenance, and industrial processes worldwide. It provides cleaning and disinfection products, and products for equipment and machine upkeep. The company serves transportation, health care, and others industries; municipalities; and cleaning and property management companies. Orapi was founded in 1968 and is based in Saint-Vulbas, France. Orapi is a subsidiary of La Financiere M.G.3.F.

Details
Name: Orapi
ORAP
Exchange: ENXTPA
Founded: 1968
€22,462,712
4,584,227
Website: http://www.orapi.com
Address: Orapi
Parc Industriel de la Plaine de l'Ain,
225 allée des Cèdres,
Saint-Vulbas,
Rhône-Alpes, 01150,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ORAP Ordinary Shares Euronext Paris FR EUR 06. Apr 2000
LSE 0ICI Ordinary Shares London Stock Exchange GB EUR 06. Apr 2000
Number of employees
Current staff
Staff numbers
1,229
Orapi employees.
Industry
Specialty Chemicals
Materials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/19 21:03
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/04/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.